Evidence-based public policy making for medicines across countries: Findings and implications for the future

Brian Godman*, Joseph Fadare, Hye Young Kwon, Carolina Zampirolli Dias, Amanj Kurdi, Isabella Piassi Dias Godói, Dan Kibuule, Iris Hoxha, Sylvia Opanga, Zikria Saleem, Tomasz Bochenek, Vanda Marković-Peković, Ileana Mardare, Aubrey C. Kalungia, Stephen Campbell, Eleonora Allocati, Alice Pisana, Antony P. Martin, Johanna C. Meyer

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

31 Citations (Scopus)


Aim: Global expenditure on medicines is rising up to 6% per year driven by increasing prevalence of non-communicable diseases (NCDs) and new premium priced medicines for cancer, orphan diseases and other complex areas. This is difficult to sustain without reforms. Methods: Extensive narrative review of published papers and contextualizing the findings to provide future guidance. Results: New models are being introduced to improve the managed entry of new medicines including managed entry agreements, fair pricing approaches and monitoring prescribing against agreed guidance. Multiple measures have also successfully been introduced to improve the prescribing of established medicines. This includes encouraging greater prescribing of generics and biosimilars versus originators and patented medicines in a class to conserve resources without compromising care. In addition, reducing inappropriate antibiotic utilization. Typically, multiple measures are the most effective. Conclusion: Multiple measures will be needed to attain and retain universal healthcare.

Original languageEnglish
Pages (from-to)1019-1052
Number of pages34
JournalJournal of Comparative Effectiveness Research
Issue number12
Publication statusPublished - Aug 2021


  • COVID-19
  • antimicrobials
  • biosimilars
  • demand-side measures
  • generics
  • guidelines
  • managed entry
  • oncology
  • orphan medicines
  • quality indicators
  • statins


Dive into the research topics of 'Evidence-based public policy making for medicines across countries: Findings and implications for the future'. Together they form a unique fingerprint.

Cite this